|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Abraxis BioScience Inc., of Los Angeles, is licensing rights to develop a biosimilar version of G-CSF (granulocyte-colony stimulating factor) in North America and the European Union from Biocon Ltd., of Bangalore, India. Under the terms, Biocon will receive an up-front licensing fee and, following approval in the licensed territories, will get royalties on any product sales. Detailed financial terms were not disclosed. G-CSF, a hematopoietic growth factor, primarily is used to treat neutropenia. Biocon recently gained regulatory approval of the product in India to treat neutropenia in cancer patients.
o Alseres Pharmaceuticals Inc., of Hopkinton, Mass., and QSV ...